Tate & Lyle plc Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 61 Fair Values set on narratives written by author
TATE Community Narratives
TATE: Revenue Guidance Revisions Will Drive Near-Term Re-Rating Opportunity
Regulatory And Integration Hurdles Will Constrain Upside But Spur Revaluation
Rising Health Trends And Urbanization Will Expand Specialty Markets
Regulatory And Integration Hurdles Will Constrain Upside But Spur Revaluation
View narrativeTATE: Revenue Guidance Revisions Will Drive Near-Term Re-Rating Opportunity
View narrativeRising Health Trends And Urbanization Will Expand Specialty Markets
View narrativeTrending Discussion
No trending discussion available.
Recently Updated Narratives
TATE: Future Share Price Will Reflect Risks Around Ingredion Takeover Proposal
TATE: Ingredion Offer And Margin Delivery Will Shape Balanced Future Returns
TATE: Ingredion Offer And Margin Outlook Will Shape Balanced Future Return Potential
Snowflake Analysis
Tate & Lyle plc Key Details
- 0.22
- 45.81%
- 4.84%
- 77.5%
About TATE
- Founded
- 1903
- Employees
- 4840
- CEO
- Website
View website
Tate & Lyle plc, together with its subsidiaries, engages in the provision of ingredients and solutions to the food, beverages, and other industries in North America, Asia, Middle East, Africa, Latin America, and Europe. Its portfolio includes sweeteners, fibres, stabilisers and functional systems, hydrocolloids, and starches, proteins, and functional flours. The company’s products are used in beverages, dairy, soups, sauces and dressings, bakery and snacks, confectionery, household, clinical nutrition, industrial, meat and seafood, and personal care applications. The company has a strategic collaboration with BioHarvest Sciences Inc. The company was incorporated in 1903 and is headquartered in London, the United Kingdom.